Furthermore, OriCAR-017, another GPRC5D-targeted autologous CAR T-cell therapy, features the proprietary Ori signal activation domain to enhance memory immune cells' expansion efficiency, boosting the anti-tumor effectiveness and longevity of CAR T-cells in vivo [191]. The gene discussed is GPRC5D; the disease is neoplasm.